The medical management of abnormal uterine bleeding in reproductive-aged women

被引:112
作者
Bradley, Linda D. [1 ]
Gueye, Ndeye-Aicha
机构
[1] Cleveland Clin, Dept Obstet & Gynecol, Cleveland, OH 44106 USA
关键词
abnormal uterine bleeding; heavy menstrual bleeding; International Federation of Gynecology and Obstetrics classification; medical treatment; premenopausal women; LEVONORGESTREL INTRAUTERINE SYSTEM; MENSTRUAL BLOOD-LOSS; QUALITY-OF-LIFE; ENDOMETRIAL FIBRINOLYTIC ENZYMES; RANDOMIZED COMPARATIVE TRIAL; CONTRACEPTIVE VAGINAL RING; LEUPROLIDE ACETATE DEPOT; TRANEXAMIC ACID; DOUBLE-BLIND; ULIPRISTAL ACETATE;
D O I
10.1016/j.ajog.2015.07.044
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
In the treatment of women with abnormal uterine bleeding, once a thorough history, physical examination, and indicated imaging studies are performed and all significant structural causes are excluded, medical management is the first-line approach. Determining the acuity of the bleeding, the patient's medical history, assessing risk factors, and establishing a diagnosis will individualize their medical regimen. In acute abnormal uterine bleeding with a normal uterus, parenteral estrogen, a multidose combined oral contraceptive regimen, a multidose progestin-only regimen, and tranexamic acid are all viable options, given the appropriate clinical scenario. Heavy menstrual bleeding can be treated with a levonorgestrel-releasing intrauterine system, combined oral contraceptives, continuous oral progestins, and tranexamic acid with high efficacy. Nonsteroidal antiinflammatory drugs may be utilized with hormonal methods and tranexamic acid to decrease menstrual bleeding. Gonadotropin-releasing hormone agonists are indicated in patients with leiomyoma and abnormal uterine bleeding in preparation for surgical interventions. In women with inherited bleeding disorders all hormonal methods as well as tranexamic acid can be used to treat abnormal uterine bleeding. Women on anticoagulation therapy should consider using progestin-only methods as well as a gonadotropin-releasing hormone agonist to treat their heavy menstrual bleeding. Given these myriad options for medical treatment of abnormal uterine bleeding, many patients may avoid surgical intervention.
引用
收藏
页码:31 / 44
页数:14
相关论文
共 127 条
[1]  
American College of Obstetricians and Gynecologists, 2008, Obstet Gynecol, V112, P387, DOI 10.1097/AOG.0b013e318183fbab
[2]   A multicenter, randomized study of an extended cycle oral contraceptive (vol 68, pg 89, 2003) [J].
Anderson, FD ;
Hait, H .
CONTRACEPTION, 2004, 69 (02) :175-175
[3]   LEVONORGESTREL-RELEASING INTRAUTERINE-DEVICE IN THE TREATMENT OF MENORRHAGIA [J].
ANDERSSON, JK ;
RYBO, G .
BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1990, 97 (08) :690-694
[4]  
[Anonymous], 2013, OBSTET GYNECOL
[5]  
[Anonymous], 2013, DEP PROV PACK INS
[6]  
[Anonymous], 2009, OBSTET GYNECOL, V114, P1156, DOI [10.1097/AOG.0b013e3181c33c72, DOI 10.1097/AOG.0B013E3181C33C72]
[7]  
[Anonymous], 2004, OBSTET GYNECOL
[8]  
[Anonymous], J OBSTET GYNAECOL CA
[9]  
[Anonymous], COCHRANE DATABASE SY
[10]  
[Anonymous], 2010, Medical Eligibility Criteria for Contraceptive Use